India · Delayed Price · Currency is INR Sudeep Pharma Statistics
Total Valuation
Sudeep Pharma has a market cap or net worth of INR 99.51 billion. The enterprise value is 100.02 billion.
| Market Cap | 99.51B |
| Enterprise Value | 100.02B |
Important Dates
The next confirmed earnings date is Tuesday, August 4, 2026.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | Jul 23, 2026 |
Share Statistics
Sudeep Pharma has 112.95 million shares outstanding. The number of shares has increased by 2.80% in one year.
| Current Share Class | 112.95M |
| Shares Outstanding | 112.95M |
| Shares Change (YoY) | +2.80% |
| Shares Change (QoQ) | +0.87% |
| Owned by Insiders (%) | 37.13% |
| Owned by Institutions (%) | 14.69% |
| Float | 25.44M |
Valuation Ratios
The trailing PE ratio is 56.84 and the forward PE ratio is 51.52.
| PE Ratio | 56.84 |
| Forward PE | 51.52 |
| PS Ratio | 15.49 |
| PB Ratio | 11.08 |
| P/TBV Ratio | 12.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 143.08 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 57.85 |
| EV / Sales | 15.57 |
| EV / EBITDA | 45.09 |
| EV / EBIT | 48.30 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.09, with a Debt / Equity ratio of 0.17.
| Current Ratio | 3.09 |
| Quick Ratio | 1.91 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 0.68 |
| Debt / FCF | -9.51 |
| Interest Coverage | 29.16 |
Financial Efficiency
Return on equity (ROE) is 25.06% and return on invested capital (ROIC) is 18.11%.
| Return on Equity (ROE) | 25.06% |
| Return on Assets (ROA) | 13.68% |
| Return on Invested Capital (ROIC) | 18.11% |
| Return on Capital Employed (ROCE) | 21.29% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 12.23M |
| Profits Per Employee | 3.29M |
| Employee Count | 525 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 1.34 |
Taxes
In the past 12 months, Sudeep Pharma has paid 537.90 million in taxes.
| Income Tax | 537.90M |
| Effective Tax Rate | 23.58% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 807.05 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 58.92 |
| Average Volume (20 Days) | 194,878 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sudeep Pharma had revenue of INR 6.42 billion and earned 1.73 billion in profits. Earnings per share was 15.50.
| Revenue | 6.42B |
| Gross Profit | 4.11B |
| Operating Income | 2.07B |
| Pretax Income | 2.28B |
| Net Income | 1.73B |
| EBITDA | 2.21B |
| EBIT | 2.07B |
| Earnings Per Share (EPS) | 15.50 |
Balance Sheet
The company has 1.15 billion in cash and 1.50 billion in debt, with a net cash position of -357.77 million or -3.17 per share.
| Cash & Cash Equivalents | 1.15B |
| Total Debt | 1.50B |
| Net Cash | -357.77M |
| Net Cash Per Share | -3.17 |
| Equity (Book Value) | 8.98B |
| Book Value Per Share | 78.21 |
| Working Capital | 4.22B |
Cash Flow
In the last 12 months, operating cash flow was 695.53 million and capital expenditures -853.78 million, giving a free cash flow of -158.25 million.
| Operating Cash Flow | 695.53M |
| Capital Expenditures | -853.78M |
| Depreciation & Amortization | 137.88M |
| Net Borrowing | 102.91M |
| Free Cash Flow | -158.25M |
| FCF Per Share | -1.40 |
Margins
Gross margin is 64.04%, with operating and profit margins of 32.24% and 26.92%.
| Gross Margin | 64.04% |
| Operating Margin | 32.24% |
| Pretax Margin | 35.51% |
| Profit Margin | 26.92% |
| EBITDA Margin | 34.39% |
| EBIT Margin | 32.24% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 0.17%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 0.17% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.80% |
| Shareholder Yield | -2.63% |
| Earnings Yield | 1.74% |
| FCF Yield | -0.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Sudeep Pharma is 730.00, which is -17.05% lower than the current price. The consensus rating is "Sell".
| Price Target | 730.00 |
| Price Target Difference | -17.05% |
| Analyst Consensus | Sell |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sudeep Pharma has an Altman Z-Score of 17.62 and a Piotroski F-Score of 5.
| Altman Z-Score | 17.62 |
| Piotroski F-Score | 5 |